NCT03856866View on ClinicalTrials.gov

Hydroxychloroquine Administration for Reduction of Pexophagy

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 11, 2019

Primary Completion Date

May 5, 2020

Study Completion Date

May 5, 2020

Conditions
Zellweger SyndromePeroxisome Biogenesis Disorders
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine: 4mg/kg/day, divided bid.

DRUG

Placebo

Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.

Trial Locations (1)

M5G1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER

NCT03856866 - Hydroxychloroquine Administration for Reduction of Pexophagy | Biotech Hunter | Biotech Hunter